[
  {
    "ts": null,
    "headline": "Why Pfizer (PFE) Outpaced the Stock Market Today",
    "summary": "In the most recent trading session, Pfizer (PFE) closed at $24.83, indicating a +1.04% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=f749a0a2175fe4b9f69e8bb078487ac3883e3cd829e2e410049a8f6a18f3e41e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757630705,
      "headline": "Why Pfizer (PFE) Outpaced the Stock Market Today",
      "id": 136711420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Pfizer (PFE) closed at $24.83, indicating a +1.04% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=f749a0a2175fe4b9f69e8bb078487ac3883e3cd829e2e410049a8f6a18f3e41e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) and Greenstone Face US$71 Million Settlement in Antitrust Lawsuit",
    "summary": "Pfizer (PFE) recently announced proposed class action settlements totaling approximately $71 million related to allegations of antitrust violations, while also facing a patent infringement lawsuit over its COVID-19 antiviral, Paxlovid. Despite these legal challenges, Pfizer's share price remained largely flat over the past month, reflecting broader market stability amidst record highs in major U.S. stock indexes. Meanwhile, positive developments in their COVID-19 vaccine trials and FDA...",
    "url": "https://finnhub.io/api/news?id=2aa02c17845e4d3cce1fbe4a07064266cb8144368502a9872896bfb2d7e22d5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757615553,
      "headline": "Pfizer (PFE) and Greenstone Face US$71 Million Settlement in Antitrust Lawsuit",
      "id": 136704127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) recently announced proposed class action settlements totaling approximately $71 million related to allegations of antitrust violations, while also facing a patent infringement lawsuit over its COVID-19 antiviral, Paxlovid. Despite these legal challenges, Pfizer's share price remained largely flat over the past month, reflecting broader market stability amidst record highs in major U.S. stock indexes. Meanwhile, positive developments in their COVID-19 vaccine trials and FDA...",
      "url": "https://finnhub.io/api/news?id=2aa02c17845e4d3cce1fbe4a07064266cb8144368502a9872896bfb2d7e22d5d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) and BioNTech SE Announce Positive Topline Results From an Ongoing Phase 3 Clinical Trial",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best growth stocks under $50 to buy now. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort “evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® 2025-2026 Formula in adults […]",
    "url": "https://finnhub.io/api/news?id=572a7d95d0d0096bc88dfe15d2910d75bb333250c324d52dec82fb188064f11c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757612943,
      "headline": "Pfizer (PFE) and BioNTech SE Announce Positive Topline Results From an Ongoing Phase 3 Clinical Trial",
      "id": 136704128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best growth stocks under $50 to buy now. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort “evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® 2025-2026 Formula in adults […]",
      "url": "https://finnhub.io/api/news?id=572a7d95d0d0096bc88dfe15d2910d75bb333250c324d52dec82fb188064f11c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=6cb8d4824f3b2720f7a4c459c7555a269503a7e863125a6de10d0bb64baa3361",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757608620,
      "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 136715156,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=6cb8d4824f3b2720f7a4c459c7555a269503a7e863125a6de10d0bb64baa3361"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE), Astellas Post Favorable Trial Results for Bladder Cancer Combo",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy. On August 12, Pfizer and Astellas Pharma reported that their combination therapy for muscle-invasive bladder cancer had positive outcomes in a Phase 3 trial, specifically for patients who cannot undergo cisplatin-based chemotherapy. In the EV-303 study, patients were treated with PADCEV and KEYTRUDA […]",
    "url": "https://finnhub.io/api/news?id=43494cd505b3083a1f4bb01a266a16191cae69246f10b123911b290c44a23957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757607610,
      "headline": "Pfizer (PFE), Astellas Post Favorable Trial Results for Bladder Cancer Combo",
      "id": 136704129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy. On August 12, Pfizer and Astellas Pharma reported that their combination therapy for muscle-invasive bladder cancer had positive outcomes in a Phase 3 trial, specifically for patients who cannot undergo cisplatin-based chemotherapy. In the EV-303 study, patients were treated with PADCEV and KEYTRUDA […]",
      "url": "https://finnhub.io/api/news?id=43494cd505b3083a1f4bb01a266a16191cae69246f10b123911b290c44a23957"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Comeback Accelerates",
    "summary": "Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=9819dbf0506ce6cd0bc7b590cf0449e1877f9c05cf76e3db18652b21c1f00dc1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757603327,
      "headline": "Pfizer's Comeback Accelerates",
      "id": 136702400,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221454874/image_2221454874.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=9819dbf0506ce6cd0bc7b590cf0449e1877f9c05cf76e3db18652b21c1f00dc1"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
    "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
    "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757602320,
      "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
      "id": 136703968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
      "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer",
    "summary": "Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.",
    "url": "https://finnhub.io/api/news?id=580827e731c758772aec40d1b08f43923e451206711d0a8fdb6e5d1f20f39222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757582700,
      "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer",
      "id": 136703787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.",
      "url": "https://finnhub.io/api/news?id=580827e731c758772aec40d1b08f43923e451206711d0a8fdb6e5d1f20f39222"
    }
  }
]